Haemonetics Corporation $HAE Shares Sold by Northern Trust Corp

Northern Trust Corp reduced its position in Haemonetics Corporation (NYSE:HAE) by 4.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 651,418 shares of the medical instruments supplier’s stock after selling 26,843 shares during the period. Northern Trust Corp owned about 1.30% of Haemonetics worth $41,398,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Stifel Financial Corp lifted its stake in shares of Haemonetics by 7.3% in the 4th quarter. Stifel Financial Corp now owns 14,776 shares of the medical instruments supplier’s stock valued at $1,154,000 after purchasing an additional 1,006 shares during the period. Envestnet Asset Management Inc. lifted its stake in shares of Haemonetics by 16.0% in the 1st quarter. Envestnet Asset Management Inc. now owns 55,746 shares of the medical instruments supplier’s stock valued at $3,543,000 after purchasing an additional 7,678 shares during the period. The Manufacturers Life Insurance Company lifted its stake in shares of Haemonetics by 434.8% in the 4th quarter. The Manufacturers Life Insurance Company now owns 314,067 shares of the medical instruments supplier’s stock valued at $24,522,000 after purchasing an additional 255,338 shares during the period. GAMMA Investing LLC lifted its stake in shares of Haemonetics by 11,225.0% in the 1st quarter. GAMMA Investing LLC now owns 17,667 shares of the medical instruments supplier’s stock valued at $11,230,000 after purchasing an additional 17,511 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Haemonetics by 7.5% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,396 shares of the medical instruments supplier’s stock valued at $851,000 after purchasing an additional 936 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on HAE shares. JPMorgan Chase & Co. restated a “neutral” rating and set a $62.00 price objective (down from $85.00) on shares of Haemonetics in a research report on Friday, August 8th. Wall Street Zen cut shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Tuesday, May 13th. Mizuho reduced their price objective on shares of Haemonetics from $90.00 to $70.00 and set an “outperform” rating for the company in a research report on Friday, August 8th. Barrington Research reduced their price objective on shares of Haemonetics from $95.00 to $86.00 and set an “outperform” rating for the company in a research report on Friday, August 8th. Finally, Needham & Company LLC restated a “buy” rating and set a $68.00 price objective (down from $84.00) on shares of Haemonetics in a research report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Haemonetics currently has a consensus rating of “Moderate Buy” and an average target price of $85.18.

Haemonetics Price Performance

Haemonetics stock opened at $54.44 on Friday. Haemonetics Corporation has a 52-week low of $50.68 and a 52-week high of $94.99. The firm has a market capitalization of $2.62 billion, a price-to-earnings ratio of 16.65, a PEG ratio of 1.01 and a beta of 0.40. The company has a fifty day simple moving average of $68.33 and a 200-day simple moving average of $66.09. The company has a quick ratio of 1.04, a current ratio of 1.72 and a debt-to-equity ratio of 1.04.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.09. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The business had revenue of $321.39 million during the quarter, compared to analyst estimates of $305.12 million. During the same quarter in the prior year, the firm earned $1.02 earnings per share. The company’s revenue for the quarter was down 4.4% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. On average, equities analysts anticipate that Haemonetics Corporation will post 4.55 EPS for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.